Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects

類似資料

• First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
  著者:: Kapur, Anita, 等
  出版事項: (2013)
• Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes
  著者:: Mudaliar, Sunder, 等
  出版事項: (2012)
• Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
  著者:: Hussey, Elizabeth K, 等
  出版事項: (2013)
• Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin
  著者:: Dobbins, Robert, 等
  出版事項: (2021)
• Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
  著者:: Mohan, Viswanathan, 等
  出版事項: (2020)